CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

Carcinogenesis, Mutagenesis, Impairment of Fertility. No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

PREGNANCY SECTION.

Pregnancy: Teratogenic Effects. Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. The frequency of adverse events reported in patients using nystatin ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.).

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY. Pharmacokinetics. Nystatin is not absorbed from intact skin or mucous membrane.. Microbiology. Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing concentrations of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

CONTRAINDICATIONS SECTION.

CONTRAINDICATIONS. Nystatin ointment is contraindicated in patients with history of hypersensitivity to any of their components.

DESCRIPTION SECTION.

DESCRIPTION. Nystatin is polyene antifungal antibiotic drug obtained from Streptomyces nursei. Structural formula: Molecular formula C 47H 75NO 17 Molecular weight 926.09 g/mol Nystatin ointment is for dermatologic use. Nystatin ointment for topical use contains 100,000 USP nystatin units per gram in an ointment base of light mineral oil and white petrolatum. Image.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. Nystatin Ointment Adults and Pediatric Patients (Neonates and Older): Apply liberally to affected areas twice daily or as indicated until healing is complete.

HOW SUPPLIED SECTION.

HOW SUPPLIED. Nystatin ointment USP, 100,000 units per gram is pale yellow to yellow color ointment available as follows:NDC 13668-534-01 15 gram tubeNDC 13668-534-02 30 gram tubeSTORAGEStore at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Manufactured by:TORRENT PHARMACEUTICALS LTD., Pithampur-454775, INDIA Manufactured for:TORRENT PHARMA INC., Basking Ridge, NJ 079208063926 Revised June 2018. Image.

INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE. Nystatin ointment is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nystatin ointment is not indicated for systemic, oral, intravaginal or ophthalmic use.

INFORMATION FOR PATIENTS SECTION.

INFORMATION FOR PATIENTS. Patients using these medications should receive the following information and instructions: 1. The patient should be instructed to use these medications as directed (including the replacement of missed doses). These medications are not for any disorder other than that for which they are prescribed. 2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests. If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.. Carcinogenesis, Mutagenesis, Impairment of Fertility. No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy: Teratogenic Effects. Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers. It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for nursing woman. Pediatric Use. Safety and effectiveness have been established in the pediatric population from birth to 16 years.See DOSAGE AND ADMINISTRATION.

LABORATORY TESTS SECTION.

Laboratory Tests. If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

MICROBIOLOGY SECTION.

Microbiology. Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing concentrations of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

NURSING MOTHERS SECTION.

Nursing Mothers. It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for nursing woman.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL. Nystatin Ointment, USP 15 grams (Tube label)Nystatin Ointment, USP 15 grams (Carton label)Nystatin Ointment, USP 30 grams (Tube label)Nystatin Ointment, USP 30 grams (carton label). Tube Label of 15 g. Carton Label of 15 g. Tube Label 30 g. Carton Label 30 g.

PEDIATRIC USE SECTION.

Pediatric Use. Safety and effectiveness have been established in the pediatric population from birth to 16 years.See DOSAGE AND ADMINISTRATION.

PHARMACOKINETICS SECTION.

Pharmacokinetics. Nystatin is not absorbed from intact skin or mucous membrane.

PRECAUTIONS SECTION.

PRECAUTIONS. General Nystatin ointment should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.